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CollagenThe discoidin domain receptors, DDR1 and DDR2, are two closely related receptor tyrosine kinases that are
activated by triple-helical collagen in a slow and sustained manner. The DDRs have important roles in embryo
development and their dysregulation is associated with human diseases, such as ﬁbrosis, arthritis and cancer.
The extracellular region of DDRs consists of a collagen-binding discoidin (DS) domain and a DS-like domain.
The transmembrane region mediates the ligand-independent dimerisation of DDRs and is connected to the
tyrosine kinase domain by an unusually long juxtamembrane domain. The major DDR binding site in ﬁbrillar
collagens is a GVMGFO motif (O is hydroxyproline), which is recognised by an amphiphilic trench at the top
of the DS domain. How collagen binding leads to DDR activation is not understood. GVMGFO-containing
triple-helical peptides activate DDRs with the characteristic slow kinetics, suggesting that the supramolecular
structure of collagen is not required. Activation can be blocked allosterically by monoclonal antibodies that
bind to the DS-like domain. Thus, collagen most likely causes a conformational change within the DDR
dimer, which may lead to the formation of larger DDR clusters. This article is part of a Special Issue entitled:
Emerging recognition and activation mechanisms of receptor tyrosine kinases.© 2012 Elsevier B.V. Open access under CC BY license.1. Introduction
Receptor tyrosine kinases (RTKs) are a large family of transmem-
brane proteins that consist of a variable ligand-binding extracellular
region (ectodomain), a single membrane-spanning region, and a con-
served cytosolic tyrosine kinase domain. Signalling by RTKs critically
controls many fundamental cellular processes, such as proliferation,
differentiation, survival and migration [1,2]. The human genome en-
codes 58 RTKs, which are divided into 20 subfamilies according to
the modular architecture of their ectodomains [1]. The subject of
this review is the discoidin domain receptor (DDR) subfamily,
which in vertebrates has two members, DDR1 and DDR2. In particu-
lar, we focus on the structural basis of ligand recognition by DDRs
and how they might become activated following ligand binding. The
downstream signalling pathways and the roles of DDRs in human dis-
ease are discussed in several recent reviews [3–5].
The DDRs were discovered by homology cloning in searches for
novel RTKs [6–12]. The deﬁning feature of the DDRs is the presence of
a discoidin (DS) domain in their extracellular region. The DS domain
was originally described in the discoidin I protein of the slime mold
Dictyostelium discoideum [13]; an alternative name for the DS domain, discoidin; ECM, extracellular
dy; RTK, receptor tyrosine ki-
ing recognition and activation
enester).
Y license.is factor 5/8 type C domain due to the presence of homologous domains
in the blood coagulation factors V and VIII [14,15]. Another feature of
the DDRs that was noticed immediately is that they contain an unusual-
ly long cytosolic juxtamembrane (JM) region linking the transmem-
brane (TM) region to the tyrosine kinase domain. The most atypical
property of the DDRs, however, turned out to be the nature of their ac-
tivating ligand (whichwas unknownwhen the receptors were cloned).
The prototypical RTKs, exempliﬁed by the epidermal growth factor re-
ceptor, are activated by small soluble proteins and a similar situation
might have been expected for the DDRs. The search for the DDR ligand
was carried out independently by two laboratories and yielded the
surprising result that the DDRs are activated by collagen [16,17], a
major component of the vertebrate extracellular matrix (ECM) [18].
Vogel et al. found that cells expressing DDR1 showed robust receptor
phosphorylation when Matrigel, a mixture of ECM proteins secreted
by Engelbreth–Holm–Swarm mouse sarcoma cells, was added to the
culture medium [17]. Shrivastava et al. used DDR-Fc fusion proteins to
isolate from the surface of cancer cells a large DDR-binding protein
that was characterised by a high content of glycine, proline and hy-
droxyproline [16]. From these initial observations, both teams went
on to identify collagen as the DDR ligand, thus attributing for the ﬁrst
time a direct role for the ECM in RTK signalling [16,17]. Until then, the
ECM had been believed to contribute to RTK signalling only indirectly
by capturing and storing growth factors [19], and a signalling role of col-
lagen had only been described for integrins and the platelet receptor,
glycoprotein VI [4,20,21]. Importantly, DDR activation by collagen was
shown to be independent of β1 integrins [22]. Both DDRs are activated
by ﬁbrillar collagens (mainly types I, II and III), whilst their preferences
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speciﬁc for type IV and type X collagen, respectively [16,17,23]. DDR ac-
tivation strictly requires collagen to be in its native, triple-helical, con-
formation; heat-denatured collagen (gelatin) is not recognised by the
DDRs [16,17].
Ligand binding to prototypical RTKs results in the autophospho-
rylation of speciﬁc cytosolic tyrosine residues within seconds to mi-
nutes of stimulation, followed by the rapid down-regulation of the
signal [1,2]. In contrast, treatment of DDR-expressing cells with colla-
gen results in slow and sustained DDR phosphorylation that lasts up
to several hours [16,17]. The mechanism underlying this slow activa-
tion kinetics is unknown and should be studied with urgency.
The biological outcomes of DDR activation and the role of DDRs in
human diseases are only partly understood. The DDRs are widely
expressed in mammalian tissues and regulate cell adhesion, migra-
tion, proliferation and differentiation [3,4], as well as the remodelling
of the ECM by matrix metalloproteinases [24,25]. Mice lacking DDR1
or DDR2 are viable, but display impaired growth and a variety of
other defects. The impaired skeletal growth in Ddr2−/− mice is due
to reduction in chondrocyte proliferation [26] and mirrored by a
rare form of dwarﬁsm in humans resulting from mutations in the
DDR2 gene, termed spondylo-meta-epiphyseal dysplasia short limb-
hand type [27,28]. The phenotype of the Ddr1−/− mice includes fe-
male infertility, as well as defects in the mammary gland [29], kidney
[30] and inner ear [31]. Mice with a spontaneous deletion that removes
most of the Ddr2 gene (slie mice) are infertile due to a gonadal
dysregulation [32]. Aberrant DDR function in humans is implicated inﬁ-
brotic disorders of several organs, atherosclerosis, arthritis, and various
cancers [3–5]. Similarly to other RTKs, the DDRs are recognised as po-
tentially valuable therapeutic targets [5].
2. Primary sequence and domain organisation of DDRs
Invertebrates have DDR genes, but whether the encoded proteins
function as collagen receptors is not known [4]. All vertebrates have
two DDRs, with a typical sequence identity of ~50% between DDR1
and DDR2. The human DDR1 gene has 17 exons that are alternatively
spliced to generate ﬁve DDR1 isoforms (a–e) that differ in the cyto-
plasmic region [10,33]. DDR1a and DDR1b are the most widely dis-
tributed isoforms [3]. DDR1a lacks a 37-residue segment in the
cytosolic JM region of DDR1b that contains important phosphoryla-
tion sites. The d and e isoforms lack all or a part of the tyrosine kinase
domain and are predicted to be inactive. The human DDR2 gene has
19 exons and encodes a single isoform. The extracellular regions of
DDRs consist of an N-terminal DS domain that contains the collagen-
binding site (~160 residues) [34,35], followed by a recently described
DS-like domain (~180 residues) [36], and an extracellular JM region
that is poorly conserved between DDR1 and DDR2 (50 residues in
human DDR1, 32 residues in human DDR2) (Fig. 1). N-linked glycosyl-
ation sites are present in the DS-like domain and the extracellular JM
region, which additionally contains several predictedO-linked glycosyl-
ation sites. Following the TM region, there is a large cytosolic JM region
(170 residues in DDR1b and DDR1c, 143 residues in DDR1a, 142 resi-
dues in DDR2) and, ﬁnally, the tyrosine kinase domain. The cytoplasmic
tails of DDRs are unusually short and devoid of tyrosine residues.
Crystal structures have been determined of the DS/DS-like tandem
of DDR1 in complex with an antibody Fab fragment [36] and of the DS
domain of DDR2 bound to a collagen-like peptide [37]. There also ex-
ists a solution structure of the free DDR2 DS domain [38]. These struc-
tures are described in the following paragraphs. No experimental
structures are currently available of the tyrosine kinase domains of
DDR1 or DDR2, but their homology to tyrosine kinase domains of
known structure allows them to be modelled. Homology models
based on the tyrosine kinase domains of c-Abl, insulin receptor and
MuSK have been used to explain the inhibition of DDRs by imatinib,
nilotinib and dasatinib [39]. To what extent the unusually long JMregions of DDRs are structured is unknown and an important ques-
tion for further study.3. The DS domain: structural basis of collagen binding
Mutagenesis experiments based on homology models of the DDR
DS domain established that several predicted loop regions are essen-
tial for collagen binding and receptor activation [35,40]. The solution
structure of the DDR2 DS domain [38] conﬁrmed the predicted factor
5/8 type C fold, which consists of an eight-stranded β-barrel arranged
in two antiparallel β-sheets (β1–β2–β7–β4–β5 sheet and β6–β3–β8
sheet) (Fig. 2A). At the bottom of the β-barrel, the β2–β3 and β6–β7
connections form a ﬂat surface, and the N- and C-termini of the DS
domain are held together by a strictly conserved disulphide bridge
[14,15]. The top of the barrel is characterised by ﬁve protruding
loops, a common feature of DS domains, with loops L1–L3 connecting
strands β1 and β2, L4 connecting β3 and β4, and L6 connecting β7
and β8. According to the earlier mutagenesis studies, loops L1, L2
and L4 are involved in collagen binding to DDR2 [35]. The footprint
of collagen II on DDR2 was mapped by transferred cross-saturation
experiments [38] and identiﬁed the following residues as important
for collagen binding: Trp52 (L1); Arg105, Ile112 and Glu113 (L4);
Met174 and Asn175 (L6); and the Cys73-Cys177 disulphide bridge at
the bottomof the trench formedby loops L1–3, L4 and L6 (Fig. 2A). A ge-
neric collagen triple helix was docked computationally to this footprint,
but this model did not reveal the speciﬁc roles of the identiﬁed DDR2
residues in collagen recognition [38].
Mapping the DDR-binding sites on collagen proved challenging due
to the large size and insoluble nature of this structural ECM protein. The
ﬁbrillar collagen types I–III consist of three polypeptide chains of ~1000
residues, termed α chains, that form a right-handed triple helix with a
one-residue stagger between chains. The α chains have a characteristic
sequence of repeating glycine–X–Y residues, with positions X and Y
often occupied by proline and 4-hydroxyproline, respectively [18,41].
Type I collagen is a heterotrimer consisting of two types of α chains,
whereas collagen types II and III are homotrimers. Because of the
one-residue stagger between chains, equivalent residues in different
chains of a collagen homotrimer have non-equivalent chemical envi-
ronments. The three chains are commonly referred to as the leading,
middle and trailing chains [42].
The ﬁrst attempt to map DDR-binding sites in collagen was made
using atomic force and transmission electron microscopy [43]. These
experiments visualised DDR2 bound to the triple helix of collagen
type I, but did not identify speciﬁc binding sites. A speciﬁc DDR2-
binding site within the D2 period of type II collagen (residues
235–468 of the triple-helix) was identiﬁed using recombinant collagen
II variants, but a more detailed characterisation of the binding site
was not possible using these reagents [44]. A systematic analysis of
DDR-collagen interactions was made possible by the development of
the Collagen Toolkits, which are libraries of overlapping triple-helical
peptides that collectively represent the entire triple helix of
homotrimeric collagens [45]. Experiments with the collagen II Toolkit
revealed three major binding sites for DDR2 in type II collagen: triple
helix residues 217–243, 397–405 and 775–801 [46]. The central site,
which is locatedwithin the D2 period previously identiﬁed to be impor-
tant [44] and conserved in type III collagen, was investigated in detail.
The use of truncated and alanine-substituted peptides established that
the minimal DDR2 binding sequence in the central site is GVMGFO (O
is hydroxyproline; Fig. 2B) [46]. Remarkably, this motif overlaps with
the binding sites for two other, structurally unrelated, proteins: von
Willebrand factor, a plasma protein whose interaction with collagen
contributes to haemostasis [47,48]; and SPARC, a small glycoprotein
that modulates collagen assembly [49,50]. The functional relevance (if
any) of DDRs, von Willebrand factor and SPARC sharing a binding site
in collagen is unclear.
Fig. 1. Schematic representations of human DDR1b and DDR2. The domain boundaries are indicated for the discoidin (DS) domain, the DS-like domain, the TM region, and the ty-
rosine kinase domain. The cell membrane is represented by a grey bar. The DDR1a splice variant lacks residues 506–542 (shown in orange). Predicted N- and O-linked glycosylation
sites are indicated by magenta and green hexagons, respectively. Biochemically veriﬁed phosphorylation sites are shown in the cytoplasmic juxtamembrane regions and the acti-
vation loop of the tyrosine kinase domains. The overall sequence identity between human DDR1b and DDR2 is 52.8% (58.9% in the DS domain, 50.8% in the DS-like domain, 68.2% in
the kinase domain).
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design of a triple-helical collagen-like peptide for co-crystallisation
with the DS domain. The resulting crystal structure [37] revealed
that the DDR2 DS domain interacts with two of the three GVMGFO
motifs in the collagen-like peptide. In accordance with the collagen
footprint determined previously [38], the triple helix is bound in a
trench that is created by the protruding L1, L2, L4 and L6 loops at
the top of the DS domain (Fig. 2C). One wall and the ﬂoor of the
trench are delineated by apolar residues (Trp52, Thr56, Asn175,
Cys73–Cys177), whilst the other wall is made up of a salt bridge be-
tween Arg105 and Glu113, and the side chain of Asp69. The amphi-
philic trench binds the methionine of the leading chain and the
phenylalanine of the middle chain, and the Arg105-Glu113 salt bridge
forms two hydrogen bonds with the hydroxyl group of the hydroxy-
proline of the leading chain. These interactions are critical, as shown
by the lack of DDR2 binding to peptides in which either M, F or O of
the GVMGFO motif is replaced by alanine [46]. Additional interac-
tions, some of them mediated by water molecules, are made with
main chain atoms of the collagen-like peptide [37]. By revealing
that the major binding determinants are contributed by two chains
of the triple helix, the structure explains why denatured collagen is
not recognised by DDRs [16,17].
In contrast to DDR2, which binds to several Toolkit peptides derived
from type II and type III collagens, DDR1 binding is restricted to the
GVMGFO motif [51]. The residues forming the collagen-binding trenchare strictly conserved in DDR1 and DDR2, indicating a shared recogni-
tionmode of the GVMGFOmotif [37]. GVMGFO-containing peptides in-
duce DDR1 and DDR2 phosphorylation (further discussed below) [46].
In contrast, none of the other binding sites observed for DDR2 activate
the receptor [51], and GVMGFO thus may be the only functionally rele-
vant DDR-binding motif in ﬁbrillar collagens. Residues at the periphery
of the collagen-binding trench are less well conserved between DDR1
and DDR2, and these differences plausibly account for the different
speciﬁcities of DDRs towards non-ﬁbrillar collagens. Indeed, the substi-
tution of ﬁve peripheral amino acids in DDR2 with their DDR1 counter-
parts converts DDR2 into a receptor for type IV collagen [51]. The DDR1
binding site(s) in type IV collagen remain to be identiﬁed.
The afﬁnity of a single DS domain for collagen is modest. Ichikawa et
al. used surface plasmon resonance to determine a dissociation constant
of 25 μM for the binding of the DDR2 DS domain to immobilised type II
collagen [38]. In solid-phase assays with immobilised collagen, mono-
meric DDR constructs showed no detectable binding, whereas dimeric
DDR constructs bound with apparent dissociation constants in the low
nanomolar range [35]. Avidity effects are well known to amplify the
binding strength in solid-phase assays, but it is also possible that the
two DS domains in a DDR dimer co-operate in collagen binding (see
below).
The structures of the free DS domain of DDR1 (as seen in the con-
text of the ectodomain structure [36]) and the collagen-bound DS
domain of DDR2 [37] are very similar, even in the collagen-binding
Fig. 2. Structures of the DDR2 DS domain and its collagen complex. (A) Solution structure of the DS domain of human DDR2 (PDB code 2Z4F) [38]. The eight β-strands are labelled
1-8 and the N- and C-termini are indicated. The loops at the top of the DS domain are labelled L1–L4 and L6. Disulphide bridges are shown as sticks with yellow sulphur atoms.
Selected residues involved in collagen binding (Trp52, Arg105, Glu113, and Asn175) are shown as sticks and are labelled. (B) Structure of the GVMGFO motif (O is hydroxyproline)
in the homotrimeric collagen peptide used for co-crystallisation (PDB code 2WUH) [37]. Note the one-residue stagger between chains, which are referred to as the leading, middle
and trailing chains [42]. The amino acids of the GVMGFO motif are labelled in the trailing chain. (C) Close-up view of the collagen-binding site in the crystal structure of the DS
domain of human DDR2 bound to the GVMGFO-containing collagen peptide (PDB code 2WUH) [37]. The methionine of the collagen leading chain (M) and phenylalanine of the
middle chain (F) are accommodated in a trench at the top of the DS domain, between Trp52 and the Arg105-Glu113 salt bridge. The hydroxyproline of the collagen leading
chain (O) forms hydrogen bonds with the Arg105-Glu113 salt bridge (shown as dashed lines).
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ation contrasts with collagen binding to integrins, which is accompa-
nied by large-scale conformational changes in the receptor that are
linked to the process of transmembrane signalling [42,52].4. The DS-like domain
The recent structure determination of the near-complete DDR1
ectodomain bound to the Fab fragment of an inhibitory monoclonal
antibody (mAb) revealed that the domain following the DS domain
adopts a similar eight-stranded β-barrel fold (r.m.s. deviation of
3.1 Å for 121 aligned Cα atoms), despite a sequence identity of only
9% [36]. To reﬂect this distant relationship, the second DDR domain
was termed the DS-like domain. The β-barrel of the DS-like domain
is elaborated by a long insertion between strands β1 and β2, con-
taining ﬁve additional strands, two N-linked glycosylation sites and
a calcium-binding site (Fig. 3). The DS-like domain lacks the di-
sulphide bond that links the N- and C-termini of DS domains, but con-
tains three conserved cysteines in other locations. Two cysteines
(Cys303 and Cys348 in DDR1) form an internal disulphide bridge
linking strands β4 and β7; the unpaired cysteine (Cys287 in DDR1)
is also buried and can be mutated without compromising DDR func-
tion [53]. The crystal structure is at variance with the suggestion
that Cys303 and Cys348 mediate the covalent dimerisation of DDR1
[53]. The DS and DS-like domains of DDR1 are connected by a short
linker and form a compact assembly, in which the two domains are
related by a ~90° rotation. An extensive interface is formed between
the ﬂat bottom of the DS domain and the long insertion between
strands β1 and β2 of the DS-like domain. Although the interfaceappears to be stable, it cannot be excluded that DDR activation is
accompanied by substantial changes in the ectodomain arrangement,
as seen in the epidermal growth factor receptor, for instance [54]. The
DS-like domain of DDR1 is connected to the TM helix by a 50-residue
JM region that is rich in proline and predicted glycosylation sites. The
extracellular JM region of DDR2 is somewhat shorter (32 residues).
These JM regions could plausibly form extended stalks that would
project the globular heads of the DDR ectodomains a considerable
distance (up to 150 Å for DDR1) from the cell surface.
The crystallisation of the DDR1 ectodomain was facilitated by the
Fab fragment of mAb 3E3, which belongs to a series of anti-DDR1
mAbs that block the collagen-induced phosphorylation of DDR1 allo-
sterically, i.e. without interfering with collagen binding [36]. The 3E3
Fab fragment is bound to the DS-like domain of DDR1, near the
C-terminus of the crystallised construct. Two other blocking mAbs
(1F7 and 1F10) also have their epitopes in this region, whilst three
mAbs (3G10, 3H10 and 7A9) bind to a different epitope on the oppo-
site face of the DS-like domain. The mAbs likely inhibit DDR1 activa-
tion by sterically hindering a conformational change or oligomeric
association that is required for TM signalling.5. Mechanism of DDR activation
It seems highly unlikely that the slow activation of DDRs in re-
sponse to collagen [16,17] is solely due to conformational changes
within the receptor or simple molecular association or dissociation
events at the DDR cytosolic region. Rather, DDR activation might be
limited by a cellular process, such as the redistribution of DDR (or an-
other molecule essential for activation) in the cell membrane or their
Fig. 3. Structure of the ectodomain of DDR1. Shown are two orthogonal views of the human DDR1 ectodomain lacking the juxtamembrane region, as seen in a co-crystal structure
with a monoclonal antibody Fab fragment (PDB code 4AG4) [36]. The DS domain is in light pink and the DS-like domain in light blue. The eight core β-strands of the DS-like domain
are labelled 1–8 and the N- and C-termini are indicated. The Fab fragment, which is not shown for clarity, is bound near the C-terminus to the β3 strand and the β6-β7 loop of the
DS-like domain. Disulphide bridges are shown as sticks with yellow sulphur atoms. A calcium ion is shown as a green sphere. Two N-linked glycans are shown in grey and the mod-
iﬁed asparagines are labelled. Residues involved in collagen binding (Trp52, Arg105, and Glu113) or required for DDR signalling (conserved patch: Arg32, Leu99, and Leu152) are
shown as sticks and are labelled. A protruding loop in the DS-like domain (see text) is highlighted in magenta.
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low ﬂuorescent protein has been shown to be clustered within mi-
nutes of collagen binding [55]; it will be important to conﬁrm this
effect with untagged DDRs. Biochemical studies have shown that
DDR2 activation requires the phosphorylation by Src of speciﬁc tyro-
sines in the activation loop of the DDR2 tyrosine kinase domain
[56,57]; Src appears to be similarly involved in DDR1 activation
[58]. Following phosphorylation by Src, the activated kinase domain
of DDRs is believed to autophosphorylate several tyrosines in the JM
region, which then recruit adaptor proteins such as Shc1 [17,56]
and Nck2 [59], the protein tyrosine phosphatase SHP-2 [60], and
members of the STAT family of transcription factors [60]. A recent
proteomics study, in which DDR1b autophosphorylation was induced
by pervanadate treatment (which inhibits protein tyrosine phospha-
tases), found three phosphorylated tyrosine residues within the JM
region: Tyr484, Tyr513 and Tyr521 [61]. Three proteins were signiﬁ-
cantly enriched in immunoprecipitated activated DDR1b: the adap-
tors Shc1 and Grb2 and the RTK EphA2 [61]. Further experiments
with phosphopeptides representing all possible tyrosine phosphory-
lation sites in DDR1 retrieved additional interactors, but it remains
to be seen how many of them interact functionally with activated
DDR1 in cells. The downstream signalling pathways activated by
DDRs are not completely understood. Various studies have implicated
the mitogen-activated protein kinase, phosphoinositide 3-kinase,
Janus kinase and NF-kB pathways [4,5].
The central question for structural biologists is how ligand binding is
converted into receptor activation. It was originally proposed that RTK
activation is the result of ligand-induced receptor dimerisation, which
brings the cytosolic tyrosine kinase domains into close proximity and
thereby favours trans-autophosphorylation [2]. Many RTKs indeed
seem to follow this scheme, but how ligands cause RTK dimerisation
has turned out to be surprisingly variable [1]. Some RTK ligands are
homodimers (e.g. nerve growth factor), providing a straightforward
route to receptor dimerisation. Other RTK ligands are monomers (e.g.epidermal growth factor) and cause dimerisation by altering the struc-
ture of the receptor. However, the conceptually attractivemechanismof
ligand-induced RTK dimerisation is complicated by the observation that
many RTKs form non-covalent dimers even in the absence of a ligand
[62–64].
Collagens form supramolecular assemblies with multiple binding
sites for cellular receptors [18] and it is tempting to think that cluster-
ing by their multivalent ligands is what activates DDRs. However,
there is little experimental evidence to support this mechanism.
First of all, the oligomeric state of collagen in a typical activation ex-
periment is poorly deﬁned. Fibrillar collagens are soluble only at
low pH, where they exist as isolated triple helices. Once added to
the cell culture medium at neutral pH, the triple helices begin to ag-
gregate into ﬁbrils, and it is, therefore, difﬁcult to know what oligo-
meric species activates the DDRs. An important experiment would
be to test DDR activation by native collagen ﬁbrils. The clearest evi-
dence that the ﬁbrillar state is not required for DDR activation
comes from the observation that triple-helical collagen-like peptides
containing the DDR-binding GVMGFO motif cause DDR phosphoryla-
tion with the same slow kinetics as a tissue-derived collagen [46,51].
This ﬁnding does not exclude that DDR clustering is important for ac-
tivation, but it indicates that ligand multivalency is not essential.
Another important property of the DDRs is that they have a high
propensity to form non-covalent dimers (or higher oligomers) within
the cell membrane. Co-expression of differently tagged DDRs, followed
by cell lysis and immunoprecipitation, demonstrated an association of
the mature, cell surface-expressed, DDR glycoform, as well as of the
intracellular biosynthetic precursors [65]. In these experiments, the
level of co-immunoprecipitation was not affected by pre-treatment
of the cells with collagen. A bacterial reporter assay (TOXCAT [66])
showed that the TM region of DDR1 has an intrinsic propensity to
form dimers [65], and a subsequent comprehensive TOXCAT study
found that the DDRs display the strongest TM interaction in the
entire RTK family [64]. Collagen-independent DDR1 association has
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tion of prolines into the TM region of DDR1 strongly impaired
collagen-induced DDR1 activation, suggesting that speciﬁc TM interac-
tions are important for DDR signalling [65].
How do the crystal structures of DDR ectodomain fragments ﬁt into
this picture? The DDR1 ectodomain lacking the JM region is monomeric
in solution [36] and the complex of the DDR2 DS domain and a
collagen-like peptide has 1:1 stoichiometry [37]. In co-crystals with
the 3E3 Fab fragment, the DDR1 ectodomain formed a dimeric crystal
lattice contact, in which a protruding loop from the DS-like domain of
one molecule interacts with a highly conserved patch on the side of
the DS domain of the neighbouring molecule [36]; this patch is distant
from the collagen-binding site at the top of the DS domain (Fig. 3). Mu-
tation of the protruding loop had no effect on DDR1 activation by colla-
gen, suggesting that the crystal lattice dimer is unlikely to correspond to
a signalling dimer on cells. In contrast, two mutations in the conserved
patch (R32E, L152E) abolished DDR1 function,without affecting surface
expression or collagen binding [36]. This result suggests that the con-
served patch on the side of the DS domain is essential for DDR function
either because it is involved in receptor-receptor contacts in the signal-
ling complex or because it provides a weak secondary collagen-binding
site (Fig. 4). Receptor–receptor contacts could be limited to a signalling
dimer or lead to the formation of receptor clusters, similarly to the situ-
ationwith EphRTKs [67,68]. A putative secondary contactwith collagen
could bemade by the other subunit in aDDRdimer orwith another DDR
dimer, thus forming collagen-linked DDR clusters (not shown). These
hypotheses are testable in principle. The GVMGFO-containing collagen
peptide uses only two of its three chains to bind to the DS domain
[37] and the third chain is a likely candidate for a secondary contact.Fig. 4. Possible mechanisms of DDR activation. (A) In the absence of collagen, inactive
DDR is dimerised by interactions between the TM regions [65]. The long cytoplasmic
JM region may be involved in DDR autoinhibition. (B) A collagen-bound active DDR
dimer, in which the conserved patch in the DS domain (shown in brown) makes
dimer contacts. Collagen triple-helices are shown as cyan ﬁlled circles. (C) An alterna-
tive active DDR dimer, in which the conserved patch contributes to collagen binding.
(D) A cluster of collagen-bound DDR dimers, in which the conserved patch makes con-
tacts between dimers.Thus, a collagen-like peptidewith only two GVMGFOmotifsmay be un-
able to activate DDR on cells, even though it would still bind to the pri-
mary site at the top of the DS domain. The chemical synthesis of the
required heterotrimeric collagen-like peptide is challenging, however.
Furthermore, the interaction between DDR ectodomains and collagen-
like peptides could be studied by analytical ultracentrifugation or elec-
tron microscopy and may reveal association states beyond a 1:1 com-
plex. Conformational changes within the presumed DDR dimer could
be studied by FRET microscopy [55]. However, to distinguish intramo-
lecular conformational changes from receptor clustering, it will be es-
sential to ﬁrst determine the oligomeric state of DDRs at the cell
surface, and how it is affected by collagen binding. This could be done
using live cell single-molecule microscopy, which has already given in-
valuable insight into the activation mechanism of other RTKs [63].
Assuming that collagen somehow changes the conformation or
oligomeric state of DDRs, how is this change translated into the acti-
vation of the cytosolic kinase domain? Given the unusually long JM
regions at either side of the cell membrane, it is difﬁcult to envisage
a tight conformational coupling of the ligand-binding ectodomain
and the cytosolic kinase domain [69]. The cytosolic JM regions of
other RTKs contribute to autoinhibition of the kinase domains by a
variety of mechanisms [70,71]. Frequently, autoinhibition is relieved
by phosphorylation of tyrosine residues in the segment directly pre-
ceding the kinase domain [70]. There is no evidence that analogous
proximal tyrosine residues are phosphorylated in activated DDRs;
rather, the experimentally veriﬁed phosphotyrosines [61] are located
~100 residues N-terminal of the kinase domain (Fig. 1). Thus, if the
cytosolic JM region is involved in DDR autoinhibition, as seems plau-
sible, the mechanism is likely to differ from those described for other
RTKs.
6. DDR mutations in human diseases
Mutations in the human DDR2 gene cause a rare form of dwarﬁsm,
spondylo-meta-epiphyseal dysplasia short limb-hand type [28]. Three
of the four identiﬁed missense mutations map to the kinase domain
(T713I, I726R, R752C) and result in retention of the mutated proteins
in the endoplasmic reticulum [27]. In contrast, the E113Kmutant is nor-
mally expressed at the cell surface, but does not bind collagen [27]. This
result is neatly explained by the crystal structure of a DDR2 DS-collagen
complex, which shows that an Arg105-Glu113 salt bridge recognises
the hydroxyproline in the GVMGFO motif (Fig. 2C).
The expression and activation status of DDRs is often increased in
human cancers [5]. In addition, somatic mutations in the DDR1 and
DDR2 genes have been found in cancer cells [72–75], but the function-
al consequences of the mutations have been studied only in a few
cases. A recent study discovered several DDR2 mutations in primary
lung squamous cell cancer (SCC) samples and cell lines [74]. A I638F
mutation in the kinase domain of DDR2 was shown to promote the
formation of cell colonies in soft agar, suggesting that the mutation
may confer an oncogenic gain-of-function phenotype. The I638F mu-
tant was also more sensitive to dasatinib inhibition than wild-type
DDR2. Inspection of the homologous c-Abl kinase domain struc-
ture [76] shows that Ile638 in DDR2 is located at the back of the active
site cleft, in the loop connecting helix αC to strand β4 (not shown).
Thus, it is plausible that the I638F mutation could increase the basal
activity of DDR2. Another DDR2 mutation, L63V, was also reported
to promote the formation of cell colonies in soft agar [74]. Leu63 is
conserved in all vertebrate DDRs and located close to the conserved
surface patch on the side of the DS domain, ~10 Å from the function-
ally critical Leu152. How the L63V mutation could produce a hyperac-
tive DDR2 is not clear; conceivably, the mutation could destabilise an
autoinhibited form of the receptor. Finally, a R105S mutation in DDR2
was detected in a patient with large cell lung carcinoma [72]. Interest-
ingly, Arg105 is a key residue in collagen recognition (Fig. 2C) and its
mutation may, therefore, inactivate the receptor. Further functional
2193F. Carafoli, E. Hohenester / Biochimica et Biophysica Acta 1834 (2013) 2187–2194studies will be important to determine whether the somatic DDR mu-
tations found in cancer cells are causal with regards to oncogenesis.
7. Concluding remarks
Since the discovery of collagen as the DDR ligand 15 years ago,
steady progress has been made in understanding the structural
basis of collagen recognition and signalling by DDRs, but major ques-
tions remain. Single collagen triple helices can activate the DDRs in
cell culture experiments, but how does this relate to DDR signalling
in vivo? Are the DDRs activated by collagen ﬁbres, which are abun-
dant in many tissues? If so, how do cells interpret the sustained signal
of tonically active DDRs? Alternatively, the DDRs may only be activat-
ed by isolated triple helices in tissues undergoing remodelling and re-
pair. Another important question that needs to be addressed is the
mechanism underlying the slow activation kinetics. Here, we expect
new insights to come from the application of live cell imaging at
single-molecule resolution. Finally, it is frustrating that the crystallo-
graphic characterisation of the DDRs has not been more informative
about the mechanism of receptor activation. It would be gratifying if
the reagents generated by these efforts (e.g. collagen peptides,
function-blocking mAbs, signalling-deﬁcient DDR mutants) could be
used to unlock the remaining mysteries.
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